Investigators at Weill Cornell Medicine have assembled the most comprehensive atlas to date of messenger RNA (mRNA) variants in the mouse and human brain. The atlas is an important new resource in understanding brain development, neuron specialization and other brain functions.
Ongoing Research Shows Promising Results for Neoadjuvant Treatment for Colorectal Cancer
April 10, 2024
Historically, immunotherapy has demonstrated limited effectiveness in a significant majority of patients with colorectal cancer.
Dr. Bishoy Faltas Named Chief Research Officer of the Englander Institute for Precision Medicine
March 29, 2024
I am excited to announce Dr. Bishoy M. Faltas has been named Chief Research Officer of the Englander Institute for Precision Medicine (EIPM), effective immediately.
Ongoing Research Shows Promising Results for Neoadjuvant Treatment for Colorectal Cancer
March 28, 2024
Historically, immunotherapy has demonstrated limited effectiveness in a significant majority of patients with colorectal cancer.
Mapping the Evolution of Urinary Tract Cancer Cells
March 18, 2024
Researchers at Weill Cornell Medicine have performed the most comprehensive analysis to date of cancer of the ureters or the urine-collection cavities in the kidney, known as upper tract urothelial carcinoma (UTUC). The study, which compared the characteristics of primary and metastatic tumors, provides new insights into the biology of these aggressive cancers and potential ways to treat them.
EIPM Researchers Earn Cancer Grand Challenges Funding Award to Study Cancer Inequity
March 6, 2024
Weill Cornell Medicine is part of an international team that has been awarded funding of up to $25 million over five years by Cancer Grand Challenges to study the causes of cancer inequities.
Deciphering the Male Breast Cancer Genome
March 5, 2024
Male breast cancer has distinct alterations in the tumor genome that may suggest potential treatment targets, according to a study by Weill Cornell Medicine investigators. They have conducted the first whole genome sequencing analysis of male breast cancer, which looked at the complete DNA landscape of tumor samples from 10 patients.
Oncologist Receives Prestigious MERIT Grant from the National Cancer Institute for Bladder Cancer Research
March 4, 2024
Bishoy M. Faltas, MD, a medical oncologist at NewYork-Presbyterian/Weill Cornell Medicine and Director of Bladder Cancer Research at the Englander Institute for Precision Medicine at Weill Cornell Medicine, was awarded a MERIT grant from the National Cancer Institute at the National Institutes of Health to advance his research into the role of APOBEC3 enzymes in metastatic bladder cancer.
Genetic signature may predict lung cancer response to immunotherapy
February 27, 2024
A new study has identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small-cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation.
The results, published Feb. 23 in Cell Medicine Reports, suggested that this “gene signature” could be used to identify a subclass of lung tumors that is more likely to be eradicated by immunotherapies.
Genetic Signature May Predict Response to Immunotherapy for Non-Small Cell Lung Cancer
February 23, 2024
A new study identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation. The results, published in Cell Medicine Reports on Feb.